Aarti Drugs Limited · NSE:AARTIDRUGS
Aarti Drugs — Investor Presentation (March 2019)
41 slides from Aarti Drugs's investor presentation, March 2019
Slide 1: Stock exchange cover letter
Corporate Office : Mahendra Industrial Estate, Ground Flool Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 40O O22. (India) Tel .: 022-2407 2249 I 2401 9025 (30 Lines) Fax.:022-2407 3462 | 2407 0144 Aarti Drugs Limited Email: admin@aartidrugs.com website : www.aartidrugs.com Manufacturers of : B
Slide 2: Investor Presentation March 2019
Investor Presentation March 2019
Slide 3: Safe Harbour Statement
Safe Harbour Statement This investor presentation has been prepared by Aarti Drugs Limited(“ADL”) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplie
Slide 4: Table Of Contents
Company Overview …………………………………………………………………………..…..04 - 16 Pharmaceutical Industry Overview & Growth Drivers …………………………..17 - 21 Table Of Contents Investment Proposition & Outlook ………………………………………………………..22 - 24 R & D Product Pipeline ………………………………………………………………………….25 - 27 Result Summary ………………………………………
Slide 5: Company Overview
Company Overview
Slide 6: Company Overview
Company Overview Aarti Drugs Limited was established in the year 1984 and forms part of $900 Million Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The Company is engaged in the manufa
Slide 7: Key facts and figures
Key facts and figures Largest producer of One of the leading producers 13 100+ 1,452 50+ Nimesulide in the world of Metformin in the world Manufacturing Countries Employees API Molecules facilities One of the Largest producer in Fluoroquinolones in the Largest producer of world Ketoconazole in the w
Slide 8: Milestones
Milestones 1984 1993 1996 1998 2003 2008 2011 2014 2015 2017 2019 Listed On BSE Limited Turnover of Approval of Turnover of Rs. 1000 Crore Rs. 100 Crores Turnover Rs. 100 Crores USFDA Plant Pinnacle Life Science Pvt. Ltd. 100% holdings in Pinnacle Life Science Pvt. Ltd. Pinnacle Life Science (Sikkim
Slide 9: Awards & Accolades
Awards & Accolades 1991-92 2001 2005 2006 2009 2012 CHEMEXCIL CHEMEXCIL AVAYA GLOBAL CONNECT AVAYA GLOBAL CONNECT PHARMEXCIL PHARMEXCIL Outstanding Performance in Outstanding Performance in Export Customer Responsiveness Customer Responsiveness Outstanding Performance in Outstanding Performance in E
Slide 10: Corporate Social Responsibility
Corporate Social Responsibility KOSBAD GIRL'S HOSTEL MURBE SMARAK AARTI DRUGS LIMITED | Investor Presentation | March 2019 9
Slide 11: Board Of Directors & Management
Board Of Directors & Management Mr. Prakash M. Patil Mr. Harshit M. Savla Mr. Harit P. Shah Mr. Rashesh C. Gogri Mr. Adhish P. Patil Chairman, MD & CEO Joint Managing Director Whole Time Director Managing Director Chief Financial Officer Shri Prakash M. Patil is Chairman, Managing Shri Harshit M. Sa
Slide 12: Business overview
Business overview Domestic market share leader in Export Clientele is well diversified with the topmost client most of its top 10 products contributing to only 5.69% of total export sales Local clientele is well diversified with the topmost client Top 10 Export clients contribute to only 20.45% of t
Slide 13: Revenue Split
Revenue Split Segment-wise Revenue Split Therapeutic wise Sales of the API Segment 1% FY 18-19 3% 2% FY 18-19 4% 3% 5% Anti-biotic 10% API 8% Anti-protozoals Formulation 41% Anti-inflamatory 9% Anti-diabetic Speciality Chemicals Anti-fungal Intermediates Cardioprotectant 13% Others Speciality 84% Ot
Slide 14: Plant Capacity
Plant Capacity Monthly Capacity 2480 Mt/m Particulars 2018-19 2017-18 2016-17 Units Mt Mt Mt Installed 29,758 25,714 22,582 Production 22,495 19,261 17,463 Captive 4,690 3,925 4,053 Net Production 17,805 15,337 13,410 AARTI DRUGS LIMITED | Investor Presentation | March 2019 13
Slide 15: Overview of facilities
Overview of facilities 1. Pinnacle Life science Pvt Ltd. o Formulation Plant WHO-GMP 1. Aarti Drugs Ltd-Sarigam 2902-04 2. Aarti Drugs Ltd-Sarigam 211/213 o WHO-GMP o WHO-GMP / COFEPRIS / CEP 1. Pinnacle Life science Pvt Ltd. 1. Aarti Drugs Ltd.E-22 3. Aarti Drugs Ltd.E-21 o Formulation Plant o Aust
Slide 16: Overview of facilities: export countries
Overview of facilities Global 1 Afghanistan 41 Iraq 81 Spain 2 Africa 42 Ireland 82 Sri Lanka 3 Algeria 43 Israel 83 Sudan 4 Argentina 44 Italy 84 Sultanate Of Oman 5 Armenia 45 Japan 85 Switzerland 46 Jordan 86 Syria Europe 6 Australia 12% 7 Bahamas 47 Kenya 87 Taiwan 8 Bangladesh 48 Korea 88 Tanza
Slide 17: Key local clientele
Key local clientele AARTI DRUGS LIMITED | Investor Presentation | March 2019 16
Slide 18: Pharmaceutical Industry Overview & Growth Drivers
Pharmaceutical Industry Overview & Growth Drivers
Slide 19: Pharmaceutical industry
Pharmaceutical industry Formulations Contract Research and Manufacturing Services (CRAMS) o Largest exporter of formulations in terms of volume, with 14 per o Fragmented market with more than 1,000 players cent market share and 12th in terms of export value. Drug formulation exports from India reach
Slide 20: Industry Going Forward
Industry Going Forward API IS THE LARGEST SEGMENT OF THE INDIAN PHARMACEUTICALS SECTOR Pharmaceutical Industry Manifold rise in public healthcare spending Increase in the size of middle class households Improvement in medical infrastructure US$ 33 Bn US$ 55 Bn Increase in the penetration of health i
Slide 21: Indian Pharmaceutical Industry
Indian Pharmaceutical Industry PHARMA EXPORT TO CONTINUE WITNESSING POSITIVE GROWTH Major Export Destinations in India’s Pharma Export in FY18 (%) o India, the third-largest pharmaceutical market in Asia, North America 15.30% o Supplies over 50 per cent of global demand for various vaccines, 40 per
Slide 22: Growth Drivers
Growth Drivers Pharma Vision 2020 by the government’s Department of India’s cost of production is approximately 33 per cent lower than Pharmaceuticals aims to make India a major hub for end-to-end that of the US. drug discovery Government has set aside an investment worth US$307.6 million (INR20 bil
Slide 23: Investment Proposition & Outlook
Investment Proposition & Outlook
Slide 24: Investment Proposition
Investment Proposition Around 75 to 100 cr CAPEX is STRONG PROCESS being done every year to Reliable in terms of IMPROVEMENT R&D, Newer capacities fuel growth for coming 5 years quality and timely COST LEADERSHIP, established since last GREEN FIELD considering higher gestation period deliveries. Hon
Slide 25: Outlook
Outlook ANTI DIABETIC: SPECIALITY CHEMICALS: o Started with the commercial operations, received WHOGMP, recently inspected by COFEPRIS Incremental expansion of our multipurpose chloro-sulphonation line in existing block and another dedicated o CEP approval in 2016 which opened up European markets sp
Slide 26: R & D and Product Pipeline
R & D and Product Pipeline
Slide 27: Research & Development Focus
Research & Development Focus Manufacturing facilities at Tarapur and Sarigam are supported by R&D section located at Tarapur, where R&D Expenses as % of Revenue focus is mainly on process developments STRENGTH AT R&D 0.46% Pilot plant facility at Tarapur, which is suitable to produce products on 02
Slide 28: Product Pipeline
Product Pipeline Product Under Development Product Under Pipeline Sr. No. Therapeutic Category Products Sr. No. Therapeutic Category Products 1 Alcoholism Treatment Acamprosate 1 Antidiabetic Vildagliptin 2 Anticoagulant Dabigatran 2 Antidiabetic Teneligliptin 1 Anti Cholesterol Atorvastatin 3 Antid
Slide 29: Result Summary
| > — © = E =] ”n =a =] 7) ov c
Slide 30: Results Summary – Consolidated Q4FY19 and FY19
Results Summary – Consolidated Q4FY19 and FY19 (in ₹ Million) Particulars Q4FY 19 Q3 FY 19 Q4 FY18 Y-o-Y (%) FY 19 FY 18 Y-o-Y (%) Revenue from Operations 4,591.35 3,801.07 3,306.94 39% 15,609.41 12,436.30 26% Other Income 49.91 1.68 7.68 61.76 10.49 Total Income 4,641.26 3,802.75 3,314.61 40% 15,67
Slide 31: Revenue Split – Consolidated Q4FY19
Revenue Split – Consolidated Q4FY19 Revenue EBITDA PAT 4,591 274 609 3,307 574 240 Q4 18 Q4 19 Q4 18 Q4 19 Q4 18 Q4 19 API Formulation Specialty Chemicals Intermediate & Others Q419 3,905 399 143 144 Q418 2,759 293 109 146 Note: 1.. On Consolidated Basis 2. Revenue excluding Other Income 3. EBITDA i
Slide 32: Results Summary – FY19
Results Summary – FY19 Revenue EBITDA PAT 2,135 898 15,609 12,436 1,995 823 FY 18 FY 19 FY 18 FY 19 FY 18 FY 19 API Formulation Specialty Chemicals Intermediate & Others FY19 13,086 1,498 434 591 FY18 10,168 1,390 303 575 Note: On Consolidated Basis Number In ₹ Million EBITDA is including other inco
Slide 33: Financial Overview
Financial Overview
Slide 34: Robust Financial Performance
Robust Financial Performance Revenue EBITDA & EBITDA Margin CAGR-11.20% CAGR-6.71% 16.03% 15.92% 16. 50% 2,10 0 15.41% 16. 00% 15. 50% 1,60 0 15. 00% 14. 50% 1,10 0 14. 00% 13.63% 13. 50% 600 13. 00% 11,398 11,992 12,447 15,671 1,757 1,909 1,995 2,135 12. 50% 100 12. 00% FY 16 FY 17 FY 18 FY 19 FY 1
Slide 35: Robust Financial Performance
Robust Financial Performance Earning Per Share (in ₹) Gearing Ratio (x) 1.36 38.48 1.15 1.19 33.46 34.41 0.93 28.38 FY16 FY17 FY18 FY19 FY16 FY17 FY18 FY19 Net Worth (in ₹ million) RoE(%) & RoCE (%) RoE RoCE 5,435 4,554 19.82% 20.44% 18.07% 17.97% 4,001 3,467 17.72% 17.36% 16.27% 16.66% FY16 FY17 FY
Slide 36: Profit & Loss Statement
Profit & Loss Statement (in ₹ Million) Particulars 2019 2018 2017 2016 2015 Revenue from operations (gross) 15,609.41 12,625.70 12,880.80 12,283.05 11,796.03 Less : Excise duty - -189.40 -929.10 -934.23 -853.31 Revenue from operations (net) 15,609.41 12,436.30 11,951.70 11,348.82 10,942.72 Other Inc
Slide 37: Balance Sheet
Balance Sheet (in ₹ Million) Particulars 2019 2018 2017 2016 2015 Share Capital 235.82 235.82 238.57 242.17 242.17 Other Equity-Reserves & Surplus 5,198.64 4,318.46 3,762.75 3,224.45 2,839.36 Total Shareholders Fund 5,434.46 4,554.28 4,001.32 3,466.62 3,081.53 Non - Current Liabilities Long term bor
Slide 38: Cash Flow Statement
Cash Flow Statement (in ₹ Million) Particulars 2019 2018 2017 2016 2015 A Cash Flow from Operating Activities Net Profit before Tax and Extraordinary items 1,310.23 1,245.03 1,160.12 952.75 997.20 ADJUSTMENT FOR: - - - - - Depreciation & Amortisation 425.62 400.63 384.63 365.28 310.22 Provision for
Slide 39: Shareholder Information
Shareholder Information
Slide 40: Shareholder Information
Shareholder Information Stock Data (As on 31st March 2019) Market Capitalization (₹) Shares Outstanding Free Float Symbol (NSE/ BSE) 15,027 mn 23.58 mn 37.74% AARTIDRUGS / 524348 Stock Performance Chart (As on 31st March 2019) Ownership Summary Base = 100 ADRG.NS NIPHARM 4.95 32.79 Source: Factset,
Slide 41: Thank You
Thank You Aarti Drugs Ltd Mahendra Inds. Estate, Ground Floor, Plot No. 109‐D Road No. 29, Sion (E), Mumbai‐400 022 (India) Tel: +91 22 24019025 / 24072249 Fax: +91 22 24073462 / 24070144 E‐mail: investorrelations@aartidrugs.com